Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04144387 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.

Study acronym: CARRISMM
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Nov 2026 to Dec 2028 Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 450 to confirmed 395 · Completion date: Nov 2027 to Dec 2028 · 1 morev7 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 450 to confirmed 395
    • Completion date: Nov 2027 to Dec 2028
    • Site details revised at 90 of 90 sites
  2. Re-verified, no change to tracked fieldsv6
  3. Study sites: 89 to 90v5
  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jan 2020 to Feb 11, 2020 · Site details revised at 89 of 89 sitesv4 Show 2 more changesShow less
    • Start date changed from estimate of Jan 2020 to Feb 11, 2020
    • Site details revised at 89 of 89 sites
  5. Start date: Nov 2019 to Jan 2020v3
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a prospective open label interventional multicenter study evaluating the impact of the update multiple myeloma criteria on the natural history of smoldering myeloma in order to establish new recommendations about follow up and prognostic evaluation of smoldering myeloma.
Trial Details
NCT Number NCT04144387
Lead Sponsor Intergroupe Francophone du Myelome
Conditions Smoldering Multiple Myeloma
Enrollment 395 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov